Abstract
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by the presence of neurofibrillary tangles, constituted by tau protein, and plaques formed by amyloid-beta protein. The disease courses with high neural damage, which leads to memory loss and death. Here we analyzed the presence of CX3CL1, a chemokine expressed by neurons, in cerebrospinal fluid (CSF) samples from control subjects and patients with mild cognitive impairment and AD dementia. CX3CL1 was decreased in the CSF of AD dementia patients compared to control subjects. However, there was not difference in plasma samples from the same subjects.
Highlights
Alzheimer’s disease (AD) is the most common form of dementia (Alzheimer’s Association, 2016)
We show for the first time that neuronal CX3 chemokine ligand 1 (CX3CL1) is decreased in the cerebrospinal fluid (CSF) samples from AD dementia patients compared to those from control subjects
The concentration of CX3CL1 is reduced in AD dementia compared to mild cognitive impairment (MCI) samples but not in MCI compared to C samples
Summary
Alzheimer’s disease (AD) is the most common form of dementia (Alzheimer’s Association, 2016). Assays for the detection of proteins related to the main pathological characteristics of the disease, such as neurofibrillary tangles, amyloid plaques, and neuronal death have been developed. In this regard, the prevalence of the biomarkers identified was tested in cerebrospinal fluid (CSF) samples from AD patients and controls (Blennow and Zetterberg, 2018). Given the presence of inflammation in AD, we studied whether CX3CL1 is altered with the progression of the disease To this end, we used CSF and plasma samples from control subjects, patients with mild cognitive impairment (MCI), and patients with AD dementia
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
